VolitionRX Ltd (NASDAQ:VNRX) CFO David Matthew Kratochvil acquired 10,000 shares of the company’s stock in a transaction dated Wednesday, October 5th. The stock was purchased at an average cost of $5.00 per share, for a total transaction of $50,000.00. Following the purchase, the chief financial officer now directly owns 10,000 shares in the company, valued at approximately $50,000. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of VolitionRX Ltd (NASDAQ:VNRX) opened at 4.90 on Monday. The firm’s market capitalization is $115.25 million. VolitionRX Ltd has a 12 month low of $3.05 and a 12 month high of $5.86. The stock’s 50 day moving average price is $4.59 and its 200-day moving average price is $3.72.
VolitionRX (NASDAQ:VNRX) last issued its earnings results on Thursday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by $0.01. On average, equities research analysts predict that VolitionRX Ltd will post ($0.56) EPS for the current fiscal year.
A number of research firms have recently commented on VNRX. HC Wainwright set a $10.00 price objective on VolitionRX and gave the stock a “buy” rating in a research note on Thursday, September 8th. Rodman & Renshaw reissued a “buy” rating and issued a $10.00 price objective (down previously from $12.00) on shares of VolitionRX in a research note on Wednesday, September 7th.
VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease.
Receive News & Ratings for VolitionRX Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX Ltd and related companies with MarketBeat.com's FREE daily email newsletter.